Back to top
more

Cresco Labs Inc. (CRLBF)

(Delayed Data from OTC)

$2.18 USD

2.18
551,642

+0.02 (1.00%)

Updated May 3, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CRLBF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Cresco Labs Inc. [CRLBF]

Reports for Purchase

Showing records 101 - 120 ( 121 total )

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 101

08/17/2022

Daily Note

Pages: 5

EBITDA Slightly Above Expectations; Columbia Care Acquisition On-Track

Provider: PI Financial Corp.

Analyst: ZANDBERG J

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 102

08/12/2022

Daily Note

Pages: 5

Cannabis Industry Update: 2Q22 Week II Earnings Preview

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 103

08/03/2022

Daily Note

Pages: 10

US Cannabis Q2/22 Earnings Preview

Provider: PI Financial Corp.

Analyst: ZANDBERG J

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 104

07/19/2022

Daily Note

Pages: 14

U.S. Cannabis 2Q22 Preview: Macro Impacting NT, Legislative Progess Warming

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 25.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 105

07/11/2022

Industry Report

Pages: 8

Weekly ReHash: Operating Income Gaining Investor Interest As Industry Matures

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 106

06/13/2022

Industry Report

Pages: 8

Weekly ReHash: Alternative Cannabinoids

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 107

06/06/2022

Industry Report

Pages: 8

Weekly ReHash: Consumer Access Key - Opening More Retail Licenses

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 108

05/24/2022

Industry Report

Pages: 2

NJ Adult-Use Cannabis Update: New Recreational Stores Added to Begin Sales

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 109

05/19/2022

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 110

05/19/2022

Company Report

Pages: 9

1Q22 In-Line, Leveraging Brand Success Ahead of Acquisition Close

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 111

05/18/2022

Company Report

Pages: 7

In Line Q122 Results Demonstrate Market Share Gains, Awaiting Details on Progress with Possible Divestitures

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 112

05/18/2022

Daily Note

Pages: 5

Revenue Above Expectations as Acquisition of Columbia Care Remains On-Track

Provider: PI Financial Corp.

Analyst: ZANDBERG J

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 113

05/13/2022

Daily Note

Pages: 5

Cannabis Earnings 1Q22: Week III Preview

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 114

04/08/2022

Industry Report

Pages: 8

Weekly ReHash: CAOA Federal Reform Update and Alcohol Tier Model in Cannabis

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 115

03/25/2022

Industry Report

Pages: 8

Weekly ReHash: NJ and NY Conversion Catalyst Fueling M&A

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 116

03/24/2022

Company Report

Pages: 8

Accretive? TBD. Irony as Major Acquisition Likely to Cause “Divestitures” to Become CL’s Buzz Word for the NTM. Q421 Underwhelms Muted Expectations

Provider: Echelon Welath Partners

Analyst: SEMPLE A

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 117

03/24/2022

Company Report

Pages: 10

4Q21 Soft, Transformative Acquisition of Columbia Care, Lower PT to $12

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 12.50

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 118

03/24/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Medical - Products

Record: 119

03/23/2022

Daily Note

Pages: 5

Cresco Labs to Acquire Columbia Care

Provider: PI Financial Corp.

Analyst: ZANDBERG J

Price: 5.00

Research Provided by a Third Party

Company: Cresco Labs Inc.

Industry: Unclassified

Record: 120

03/01/2022

Daily Note

Pages: 25

4Q21 MSO Preview: Expect Flat Results & Tempered ''22 Guidance Outlooks

Provider: Roth Capital Partners, Inc.

Analyst: FORTUNE S

Price: 35.00

Research Provided by a Third Party